Biocon Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020
January 21, 2021 at 12:30 pm EST
Share
Biocon Limited announced earnings results for the third quarter ended December 31, 2020. For the third quarter, the company announced total revenue was INR 18,789 million compared to INR 17,526 million a year ago. Net income was INR 1,686 million compared to INR 2,028 million a year ago. Basic earnings per share was INR 1.42 compared to INR 1.71 a year ago. Diluted earnings per share was INR 1.4 compared to INR 1.71 a year ago. Basic earnings per share from continuing operations was INR 1.43 compared to INR 1.74 a year ago. Diluted earnings per share from continuing operations was INR 1.41 compared to INR 1.74 a year ago. For the nine months, total revenue was INR 53,232 million compared to INR 48,413 million a year ago. Net income was INR 4,873 million compared to INR 6,248 million a year ago. Basic earnings per share was INR 4.11 compared to INR 5.28 a year ago. Diluted earnings per share was INR 4.07 compared to INR 5.27 a year ago. Basic earnings per share from continuing operations was INR 4.19 compared to INR 5.45 a year ago. Diluted earnings per share from continuing operations was INR 4.15 compared to INR 5.44 a year ago.
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
BIOCON LIMITED 
